Clinical Research Directory
Browse clinical research sites, groups, and studies.
Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)
Sponsor: Catherine Bollard
Summary
The proposed study will be a prospective, open-label, single-center, safety and feasibility phase 1 trial of allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery though cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life
Official title: Mesenchymal Stromal Cells Delivery Through Cardiopulmonary Bypass in Pediatric Cardiac Surgery
Key Details
Gender
All
Age Range
Any - 6 Months
Study Type
INTERVENTIONAL
Enrollment
17
Start Date
2020-07-29
Completion Date
2026-09
Last Updated
2025-04-29
Healthy Volunteers
No
Conditions
Interventions
BM-MSC
Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.
Locations (1)
Children's National Health System
Washington D.C., District of Columbia, United States